KALA BIO, Inc. - Director's Dealing 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2020-06-09

Reporting Person: Reumuth Mary (Chief Financial Officer)

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-09	Common Stock	M	11520	$2.30	Acquired	16336	Direct
2020-06-09	Common Stock	M	5077	$5.21	Acquired	21413	Direct
2020-06-09	Common Stock	M	15360	$2.30	Acquired	36773	Direct
2020-06-09	Common Stock	M	11520	$2.30	Acquired	48293	Direct

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-09	Stock Option (right to buy)	$2.30	M	11520	Disposed	2024-10-01	Common Stock (11520)	Direct
2020-06-09	Stock Option (right to buy)	$5.21	M	5077	Disposed	2025-10-01	Common Stock (5077)	Direct
2020-06-09	Stock Option (right to buy)	$2.30	M	15360	Disposed	2024-12-03	Common Stock (15360)	Direct
2020-06-09	Stock Option (right to buy)	$2.30	M	11520	Disposed	2024-10-01	Common Stock (11520)	Direct

F1: Includes 4,816 shares acquired under the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan on June 28, 2019.

F2: The option was fully vested.

F3: The option was fully vested.

F4: The option was fully vested.

F5: The option was fully vested.